Melbourne, Aug 21, 2015 - (ABN Newswire) - Australian respiratory technology company Rhinomed Ltd (ASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.
- Mute to go on sale in UK pharmacies from late October 2015
- First step in global pharmacy distribution strategy
- Global sleep assistance market estimated at over US$32 billion
Mute is Rhinomed's over the counter snoring/sleep quality product which has been shown in trials (n=236) carried out in late 2014 to reduce snoring in 75% of participants. It is a discrete device that gently opens the nostrils to improve breathing capacity and reduce snoring. Mute is registered with the USFDA, Australian TGA and European Authority (CE Mark).
"Getting Mute into pharmacies in the UK is an important step for Rhinomed as we seek to expand our global pharmacy distribution footprint. A recent omnibus survey identified that 75% of Britons snore and 30% snore almost every night. Ensuring British snorers can purchase Mute through the high street pharmacy channel is critically important and a significant milestone achievement for the company", said CEO Michael Johnson.
According to IMS Health global spending on sleep related products has increased 8.8% annually since 2008 with the market reaching USD32 billion annually in 2012.
The Mute technology will be sold exclusively in the United Kingdom by Boots UK, the leading pharmacy-led health and beauty retailer.. Full terms, including pricing and minimum order sizes remain confidential. The exclusive distribution deal supersedes previous UK distribution deals for Mute.
WEB: UK Pharmacy Distribution Secured for Mute
About: Rhinomed Ltd
Rhinomed Limited (ASX:RNO) is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Help employers find you! Check out all the jobs and post your resume.
- Mute to go on sale in UK pharmacies from late October 2015
- First step in global pharmacy distribution strategy
- Global sleep assistance market estimated at over US$32 billion
Mute is Rhinomed's over the counter snoring/sleep quality product which has been shown in trials (n=236) carried out in late 2014 to reduce snoring in 75% of participants. It is a discrete device that gently opens the nostrils to improve breathing capacity and reduce snoring. Mute is registered with the USFDA, Australian TGA and European Authority (CE Mark).
"Getting Mute into pharmacies in the UK is an important step for Rhinomed as we seek to expand our global pharmacy distribution footprint. A recent omnibus survey identified that 75% of Britons snore and 30% snore almost every night. Ensuring British snorers can purchase Mute through the high street pharmacy channel is critically important and a significant milestone achievement for the company", said CEO Michael Johnson.
According to IMS Health global spending on sleep related products has increased 8.8% annually since 2008 with the market reaching USD32 billion annually in 2012.
The Mute technology will be sold exclusively in the United Kingdom by Boots UK, the leading pharmacy-led health and beauty retailer.. Full terms, including pricing and minimum order sizes remain confidential. The exclusive distribution deal supersedes previous UK distribution deals for Mute.
WEB: UK Pharmacy Distribution Secured for Mute
About: Rhinomed Ltd
Rhinomed Limited (ASX:RNO) is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.
Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.
The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.
Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.
Help employers find you! Check out all the jobs and post your resume.
